Grace Therapeutics, Inc. (GRCE) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Grace Therapeutics, Inc. (GRCE) Healthcare & Pipeline Overview

Grace Therapeutics, Inc., a biotechnology firm, focuses on developing and commercializing treatments for rare and orphan diseases in Canada. Their primary focus is GTX-104, an intravenous infusion for subarachnoid hemorrhage, positioning them in a niche market within the broader healthcare sector.

What Is the Investment Thesis for GRCE?

Grace Therapeutics, Inc. presents a focused investment opportunity within the rare disease biopharmaceutical sector. The company's lead product candidate, GTX-104, targeting subarachnoid hemorrhage, addresses a critical unmet need. Successful clinical trials and subsequent commercialization could drive significant revenue growth. Further potential lies in GTX-102 and GTX-101, targeting ataxia-telangiectasia and postherpetic neuralgia, respectively, diversifying the product pipeline. The company's market capitalization of $36.3M reflects its early stage, offering potential for substantial upside. However, the company's small size and limited resources, with only 4 employees, pose execution risks. Upcoming clinical trial results for GTX-104 will be a key catalyst to watch. The company's beta of 0.69 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

GRCE Key Highlights

Market capitalization of $36.3M indicates a small-cap company with potential for growth.

• Lead product candidate GTX-104 targets subarachnoid hemorrhage, a critical unmet medical need.
• Focus on rare and orphan diseases provides potential for market exclusivity and premium pricing.
• Beta of 0.69 suggests lower volatility compared to the overall market.
• Rebranded in October 2024 to focus on rare diseases, signaling a strategic shift.

Who Are GRCE's Competitors?

GRCE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are GRCE's Key Strengths?

Focus on rare and orphan diseases with high unmet medical needs.

• Lead product candidate GTX-104 targets a life-threatening condition.
• Pipeline includes multiple product candidates addressing different rare diseases.
• Strategic shift towards rare diseases with rebranding in 2024.

What Are GRCE's Weaknesses?

Small company size with limited resources (4 employees).

• Early-stage product pipeline with significant development risks.
• Dependence on successful clinical trials and regulatory approvals.
• Limited commercialization experience.

What Could Drive GRCE Stock Higher?

Clinical trial results for GTX-104 in the treatment of subarachnoid hemorrhage.

• Regulatory submissions for GTX-104 in Canada and other key markets.
• Development and advancement of GTX-102 for ataxia-telangiectasia.
• Development and advancement of GTX-101 for postherpetic neuralgia.

What Are the Key Risks for GRCE?

Negative return on equity (-14.1%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for GTX-104 or other product candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from other companies developing treatments for rare diseases.
• Limited financial resources and dependence on external funding.
• Small company size and limited infrastructure.

What Are the Growth Opportunities for GRCE?

• Expansion of GTX-104 into New Markets: Grace Therapeutics has the opportunity to expand the market reach of GTX-104 beyond Canada, targeting regions with high incidence rates of subarachnoid hemorrhage, such as the United States and Europe. The global market for subarachnoid hemorrhage treatment is estimated at $500 million annually. Securing regulatory approvals in these key markets could significantly increase revenue potential within the next 3-5 years.
• Advancement of GTX-102 for Ataxia-Telangiectasia: The development and commercialization of GTX-102, an oral mucosal betamethasone spray for ataxia-telangiectasia, represents a significant growth opportunity. Currently, there are limited treatment options available for this rare genetic disorder. Successful clinical trials and regulatory approval could establish Grace Therapeutics as a leader in this niche market, potentially generating $50-100 million in annual revenue within 5-7 years.
• Development of GTX-101 for Postherpetic Neuralgia: GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia, addresses a significant unmet need for effective pain management. The market for postherpetic neuralgia treatments is estimated at $1.2 billion globally. Successful development and commercialization of GTX-101 could capture a substantial share of this market, contributing significantly to Grace Therapeutics' revenue within 3-5 years.
• Strategic Partnerships and Collaborations: Grace Therapeutics can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations could provide access to additional funding, expertise, and distribution networks, enhancing the company's ability to bring its products to market more efficiently. Such partnerships could be established within the next 1-2 years.
• Expansion into New Therapeutic Areas: Grace Therapeutics can leverage its expertise in rare and orphan diseases to expand into new therapeutic areas with high unmet medical needs. This could involve acquiring or licensing new product candidates targeting other rare conditions, diversifying the company's pipeline and reducing its reliance on its current lead products. This expansion could begin within the next 2-3 years, focusing on areas with strong market potential and limited competition.

What Threats Does GRCE Face?

• Competition from other companies developing treatments for rare diseases.
• Regulatory hurdles and delays in obtaining approvals.
• Clinical trial failures and unexpected safety issues.
• Challenges in raising capital to fund development activities.

What Are GRCE's Competitive Advantages?

• Focus on rare and orphan diseases provides market exclusivity through orphan drug designations.
• Proprietary formulations and delivery systems for their product candidates.
• Strong intellectual property protection through patents and trademarks.
• Established relationships with key opinion leaders in the rare disease community.

What Does GRCE Do?

Grace Therapeutics, Inc., formerly known as Acasti Pharma Inc., was founded in 2002 and rebranded in October 2024 to reflect its strategic shift towards rare and orphan diseases. Headquartered in Princeton, New Jersey, the company is dedicated to the development and commercialization of pharmaceutical products addressing unmet medical needs in these specialized areas. Their lead product candidate, GTX-104, is an intravenous infusion designed to treat subarachnoid hemorrhage, a life-threatening condition involving bleeding in the space surrounding the brain. In addition to GTX-104, Grace Therapeutics is also developing GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia, a rare genetic disorder affecting coordination and immune function, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia, a painful nerve condition that can occur after shingles. The company's focus on rare diseases underscores its commitment to addressing conditions that often lack effective treatments and represent significant opportunities for innovation and market exclusivity. Grace Therapeutics operates primarily in Canada, targeting a market with established regulatory pathways for orphan drugs.

What Products and Services Does GRCE Offer?

• Develop pharmaceutical products for rare and orphan diseases.
• Focus on unmet medical needs in specialized therapeutic areas.
• Develop GTX-104, an intravenous infusion for subarachnoid hemorrhage.
• Develop GTX-102, an oral mucosal betamethasone spray for ataxia-telangiectasia.
• Develop GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
• Engage in clinical trials to evaluate the safety and efficacy of their product candidates.
• Seek regulatory approvals for their products in Canada and other markets.
• Commercialize their approved products through partnerships or direct sales.

How Does GRCE Make Money?

• Develop and patent novel pharmaceutical products for rare diseases.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from health authorities like Health Canada.
• Commercialize approved products, potentially through partnerships or direct sales.

What Industry Does GRCE Operate In?

Grace Therapeutics operates within the biotechnology industry, specifically targeting the rare and orphan disease market. This segment is characterized by high unmet medical needs and often benefits from regulatory incentives such as market exclusivity and accelerated approval pathways. The global orphan drug market is projected to reach $250 billion by 2028, reflecting a significant growth opportunity. Competition includes both large pharmaceutical companies and smaller biotech firms focusing on niche therapeutic areas. Grace Therapeutics' success will depend on its ability to navigate the complex regulatory landscape and successfully develop and commercialize its product candidates.

Who Are GRCE's Key Customers?

• Patients suffering from rare and orphan diseases.
• Hospitals and clinics that treat these patients.
• Specialty pharmacies that dispense rare disease medications.
• Healthcare providers who prescribe these medications.

Return on equity for Grace Therapeutics, Inc. stands at -14.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.5%, the inverse of the P/E and a quick read on earnings relative to price.

Grace Therapeutics, Inc. (GRCE) Valuation Context

Valued at $36.3M, GRCE is classified as a micro-cap stock. Analyst price targets span from $4.00 to $4.00, with a consensus of $4.00. At the current price of $2.23, that implies approximately 79% upside potential. Relative to its peer group, GRCE's quantitative score of 54/100 is below the peer average of 77/100.

Company Profile

Grace Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO Prashant Kohli. GRCE has traded publicly since 2012.

Grace Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.28 places it in the safe zone, indicating low near-term bankruptcy risk.

Grace Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 51.3% below estimates on average.

Wall Street analysts project Grace Therapeutics, Inc. revenue of about $450K for fiscal 2026, with EPS near $-0.82.

Over the past six months, Grace Therapeutics, Inc. insiders filed 5 SEC Form 4 transactions — 0 sales and 5 purchases. On net that is roughly 403K shares acquired (about $854K) — insiders putting money in tends to read as conviction.

GRCE Financials

GRCE Latest News

GRCE Analyst Consensus

GRCE MoonshotScore

Grace Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources